My watch list  

Gleevec shifts APP processing from a {beta}-cleavage to a nonamyloidogenic cleavage [Neuroscience]

Neurotoxic amyloid-β peptides (Aβ) are major drivers of Alzheimer’s disease (AD) and are formed by sequential cleavage of the amyloid precursor protein (APP) by β-secretase (BACE) and γ-secretase. Our previous study showed that the anticancer drug Gleevec lowers Aβ levels through indirect inhibition of γ-secretase activity. Here we report that...

Authors:   William J. Netzer; Karima Bettayeb; Subhash C. Sinha; Marc Flajolet; Paul Greengard; Victor Bustos
Journal:   Proceedings of the National Academy of Sciences current issue
Volume:   114
edition:   6
Year:   2017
Pages:   1389
DOI:   10.1073/pnas.1620963114
Publication date:   07-Feb-2017
Facts, background information, dossiers
More about Proceedings of the National Academy of Sciences
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE